EUVIMEDEUVIMED entdecken
Multizentrische Studie

Impact of Adjuvant Chemotherapy on Resected Intraductal Papillary Mucinous Neoplasm-Derived Pancreatic Cancer: Results From an International Multicenter Study

Joseph R Habib iD, Benedict Kinny-Köster, Ammar A Javed iD, Poitr Zelga iD, Lily V Saadat, Rachel C Kim iD, Myrte Gorris iD, Valentina Allegrini, Shuichi Watanabe, Jeremy Sharib iD, Massimo Arcerito iD, Jörg Kaiser und 28 weitere

Journal of Clinical Oncology · 2024

DOI: 10.1200/jco.23.02313 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Clinical Oncology, 2024. Verfasst von Joseph R Habib und 39 weiteren Autor:innen. Beteiligte Einrichtung: New York University Grossman School of Medicine, New York, NY. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Carcinoma, Pancreatic Ductal. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 36 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE The benefit of adjuvant therapy for intraductal papillary mucinous neoplasm (IPMN)-derived pancreatic ductal adenocarcinoma (PDAC) remains unclear because of severely limited evidence. Although biologically distinct entities, adjuvant therapy practices for IPMN-derived PDAC are largely founded on pancreatic intraepithelial neoplasia-derived PDAC. We aimed to evaluate the role of adjuvant chemotherapy in IPMN-derived PDAC. METHODS This international multicenter retrospective cohort study (2005-2018) was conceived at the Verona Evidence-Based Medicine meeting. Cox regressions were performed to identify risk-adjusted hazard ratios (HR) associated with overall survival (OS). Kaplan-Meier curves and log-rank tests were employed for survival analysis. Logistic regression was performed to identify factors motivating adjuvant chemotherapy administration. A decision tree was proposed and categorized patients into overtreated, undertreated, and optimally treated cohorts. RESULTS In 1,031 patients from 16 centers, nodal disease (HR, 2.88, P < .001) and elevated (≥37 to .05). Based on this model, we observed undertreatment in 18.1% and overtreatment in 61.2% of patients. Factors associated with chemotherapy administration included younger age, R1-margin, poorer differentiation, and nodal disease. CONCLUSION Almost half of patients with resected IPMN-derived PDAC may be overtreated or undertreated. In patients with node-negative disease or normal CA19-9, adjuvant chemotherapy is not associated with a survival benefit, whereas those with node-positive disease and elevated CA19-9 have an associated benefit from adjuvant chemotherapy. A decision tree was proposed. Randomized controlled trials are needed for validation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreatic NeoplasmsCarcinoma, Pancreatic DuctalHumansFemaleChemotherapy, AdjuvantMaleRetrospective StudiesAgedMiddle AgedAdenocarcinoma, MucinousPancreatic Intraductal Neoplasms

Autor:innen und Institutionen

  • New York University Grossman School of Medicine, New York, NY.
  • Heidelberg University Hospital, Heidelberg, Germany.
  • Massachusetts General Hospital, Boston, MA.
  • Memorial Sloan Kettering Cancer Center, New York, NY.
  • Indiana University School of Medicine, Indianapolis, IN.
  • Amsterdam University Medical Center, Amsterdam, the Netherlands.

ORCID-Profile: Joseph R Habib, Ammar A Javed, Poitr Zelga, Rachel C Kim, Myrte Gorris, Jeremy Sharib, Massimo Arcerito, Kelly J Lafaro, Manish Bhandre, Camilo Correa, Lois A Daamen, Paul E Oberstein, C Max Schmidt, Matthew H G Katz, Kevin C Soares, Yi Miao, Jin He, Carlos Fernandez-Del Castillo, Marc G Besselink, Giovanni Marchegiani

Zitieren

APA

Habib, J. R., Kinny-Köster, B., Javed, A. A., Zelga, P., Saadat, L. V., Kim, R. C., Gorris, M., Allegrini, V., Watanabe, S., Sharib, J., Arcerito, M., Kaiser, J., Lafaro, K. J., Tu, M., Bhandre, M., Shi, C., Kim, M. P., Correa, C., Daamen, L. A., …, & Verona IPMN Consortium (2024). Impact of Adjuvant Chemotherapy on Resected Intraductal Papillary Mucinous Neoplasm-Derived Pancreatic Cancer: Results From an International Multicenter Study. Journal of Clinical Oncology. https://doi.org/10.1200/jco.23.02313

Vancouver

Habib JR, Kinny-Köster B, Javed AA, Zelga P, Saadat LV, Kim RC, et al. Impact of Adjuvant Chemotherapy on Resected Intraductal Papillary Mucinous Neoplasm-Derived Pancreatic Cancer: Results From an International Multicenter Study. Journal of Clinical Oncology. 2024. doi:10.1200/jco.23.02313

BibTeX
@article{Habib2024,
  author = {Habib, Joseph R and Kinny-Köster, Benedict and Javed, Ammar A and Zelga, Poitr and Saadat, Lily V and Kim, Rachel C and Gorris, Myrte and Allegrini, Valentina and Watanabe, Shuichi and Sharib, Jeremy and Arcerito, Massimo and Kaiser, Jörg and Lafaro, Kelly J and Tu, Min and Bhandre, Manish and Shi, Chanjuan and Kim, Michael P and Correa, Camilo and Daamen, Lois A and Oberstein, Paul E and Schmidt, C Max and Hanna, Nader N and Allen, Peter and Loos, Martin and Shrikhande, Shailesh V and Molenaar, I Quintus and Frigerio, Isabella and Katz, Matthew H G and Soares, Kevin C and Miao, Yi and Del Chiaro, Marco and He, Jin and Hackert, Thilo and Salvia, Roberto and Büchler, Markus W and Castillo, Carlos Fernandez-Del and Besselink, Marc G and Marchegiani, Giovanni and Wolfgang, Christopher L and Verona IPMN Consortium, Verona IPMN Consortium},
  title = {Impact of Adjuvant Chemotherapy on Resected Intraductal Papillary Mucinous Neoplasm-Derived Pancreatic Cancer: Results From an International Multicenter Study},
  journal = {Journal of Clinical Oncology},
  year = {2024},
  doi = {10.1200/jco.23.02313}
}
Kostenlos starten →